# US 2020/0346047 A1 · Method and kit for home controlled ovarian stimulation for in vitro fertilization

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0346047 A1
- Document ID: US20200346047A1
- Status: Published application
- Kind: A1
- Application number: 16/867,308
- Filed: 2020-05-05
- Published: 2020-11-05
- Earliest claimed: 2019-05-01
- Assignees: Zaher Merhi; John Zhang
- Inventors: Zaher Merhi; John Zhang
- Web page: https://patentgrep.com/patent/US20200346047A1

## CPC

- A61B 10/0012: {Ovulation-period determination (for animals A61D17/002)}
- A61B 5/4839: {combined with drug delivery}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 9/0043: {Nose}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 38/09: Luteinising hormone-releasing hormone [LHRH] {, i.e. Gonadotropin-releasing hormone [GnRH]}; Related peptides
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A home controlled ovarian hyperstimulation method for in vitro fertilization (IVF) or egg freezing and a home IVF kit are described herein.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A method for home controlled ovarian stimulation in a female patient in preparation for in vitro fertilization (IVF) or egg freezing, the method comprising the steps of:
1) stimulating an increase in the amounts of hormones that support the growth and release of one or more mature eggs in the female patient;
2) suppressing luteinizing hormone (LH) release by the pituitary gland by either inserting vaginally in the female patient or administering orally to the female patient a GnRH antagonist in a therapeutically effective amount;
3) testing whether the female patient is ovulating using an ovulation predictor kit, wherein if the testing shows the female patient is ovulating, then no further medications are administered to the female patient.

### Claim 18 (depends on 17)

The method of claim 17, wherein the GnRH antagonist is elagolix, linzagolix or relugolix.

### Claim 19 (depends on 17)

The method of claim 17, wherein the GnRH antagonist is elagolix.

### Claim 20 (depends on 17)

The method of claim 17, wherein the therapeutically effective amount of the GnRH antagonist is 25 to 200 mg per day.

### Claim 21 (depends on 17)

The method of claim 17, wherein the therapeutically effective amount of the GnRH antagonist is 25 mg per day.

### Claim 22 (depends on 17)

The method of claim 17, wherein the GnRH antagonist is either inserted vaginally in the female patient or administered orally to the female patient on day 9 of the female patient's menstrual cycle.

### Claim 23 (depends on 17)

The method of claim 17, wherein the GnRH antagonist is either inserted vaginally in or administered orally to the female patient on day 9 and on day 11 of the female patient's menstrual cycle.

### Claim 24

A method for home controlled ovarian stimulation in a female patient in preparation for in vitro fertilization (IVF) or egg freezing, the method comprising the steps of:
1) stimulating an increase in the amounts of hormones that support the growth and release of one or more mature eggs in the female patient;
2) suppressing luteinizing hormone (LH) release by the pituitary gland by either inserting vaginally in the female patient or administering orally to the female patient a GnRH antagonist in a therapeutically effective amount;
3) testing whether the female patient is ovulating using an ovulation predictor kit, wherein if (a) the testing shows the female patient is ovulating, then no further medications are administered to the female patient, or (b) the testing shows the female patient is not ovulating, then the method proceeds to step 4;
4) administering a leuprorelin or nafarelin nasal spray to the female patient, in a therapeutically effective amount one or more times per day, wherein on the first day of administering the leuprorelin or nafarelin nasal spray to the female patient,
a. testing whether the female patient is ovulating using an ovulation predictor kit each time before administering the leuprorelin nasal spray to the female patient, wherein if (a) the testing shows the female patient is ovulating, then no further medications are administered to the female patient, or (b) the testing shows the female patient is not ovulating, then the method proceeds to step 5; and
5) administering a leuprorelin or nafarelin nasal spray to the female patient in a therapeutically effective amount one or more times per day for a second day, wherein on the second day of administering the leuprorelin or nafarelin nasal spray to the female patient,
a. testing whether the female patient is ovulating using an ovulation predictor kit each time before administering the leuprorelin nasal spray to the female patient, wherein if the testing shows the female patient is ovulating, then the controlled ovarian stimulation is successful.

### Claim 25 (depends on 24)

The method of claim 24, wherein the GnRH antagonist is elagolix, linzagolix or relugolix.

### Claim 26 (depends on 24)

The method of claim 24, wherein the GnRH antagonist is elagolix.

### Claim 27 (depends on 24)

The method of claim 24, wherein the therapeutically effective amount of the GnRH antagonist is 25 to 200 mg per day.

### Claim 28 (depends on 24)

The method of claim 24, wherein the therapeutically effective amount of the GnRH antagonist is 25 mg per day.

### Claim 29 (depends on 24)

The method of claim 24, wherein the GnRH antagonist is either inserted vaginally in the female patient or administered orally to the female patient on day 9 of the female patient's menstrual cycle.

### Claim 30 (depends on 24)

The method of claim 24, wherein the GnRH antagonist is either inserted vaginally in or administered orally to the female patient on day 9 and on day 11 of the female patient's menstrual cycle.

### Claim 31 (depends on 24)

The method of claim 24, wherein the therapeutically effective amount of leuprorelin or nafarelin nasal spray is three sprays per nostril, wherein each spray contains 0.05 mL of leuprorelin or nafarelin.

### Claim 32 (depends on 24)

The method of claim 24, wherein the step of administering the leuprorelin nasal spray according to step 4 or step 5 comprises:
a. administering 3 sprays of the leuprorelin or nafarelin nasal spray in each nostril of the female patient, waiting 10 minutes and repeating administering 3 sprays of the leuprorelin or nafarelin nasal spray in each nostril of the female patient;
b. waiting approximately 12 hours; and
c. administering 3 sprays of the leuprorelin or nafarelin nasal spray in each nostril of the female patient, waiting 10 minutes and repeating administering 3 sprays of the leuprorelin or nafarelin nasal spray in each nostril of the female patient.
